Craft

Hikma Pharmaceuticals

Stock Price

£19.2

2024-10-29

Market Capitalization

£4.3 B

2024-10-29

Revenue

$3.3 B

FY, 2025

Hikma Pharmaceuticals Summary

Company Summary

Overview
Hikma is a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets it serves through the development, manufacturing and marketing of a broad range of solid, liquid and injectable generic and in-licensed pharmaceutical products. Hikma is a leading generic pharmaceutical company with a significant presence in the Middle East and North Africa (MENA) region, the United States and Europe. It was first listed on the London Stock Exchange in 2005 is now a constituent of the FTSE 100 Index.
Type
Public
Status
Active
Founded
1978
HQ
London, GB | view all locations
Website
https://www.hikma.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • John Castellani

    John Castellani, Independent Non-Executive Director

    • Said Darwazah

      Said Darwazah, Executive Chairman and Chief Executive Officer

      • Pat Butler

        Pat Butler, Non-Executive Director

      • Nina Henderson

        Nina Henderson, Independent Non-Executive Director

        LocationsView all

        17 locations detected

        • London, England HQ

          United Kingdom

          1 New Burlington Place

        • Berkeley Heights, NJ

          United States

          200 Connell Drive Suite 4000

        • Staoueli, Algiers Province

          Algeria

          Zone d'Activité 15/16

        • Mississauga, ON

          Canada

          5995 Avebury Rd Suite 804

        • Boulogne-Billancourt, IDF

          France

          105 Rue Marcel Dassault

        • Martinsried, BY

          Germany

          Lochhamer Straße 13

        and 11 others

        Hikma Pharmaceuticals Financials

        Summary Financials

        Revenue (FY, 2025)
        $3.3B
        Gross profit (FY, 2025)
        $1.7B
        Net income (FY, 2025)
        $407.0M
        Cash (FY, 2025)
        $217.0M
        EBIT (FY, 2025)
        $543.0M
        Enterprise value
        $5.7B

        Footer menu